Company / SG&A Expense
BeOne Medicines Ltd. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.1B
FY2025
5-year range
$990.1M / $2.1B
FY2021-FY2025
Trend
+13.7%
vs FY2024
Sector context
#14 of 213
Health Care
What the data says
Among 213 Health Care companies, BeOne Medicines Ltd. is in the bottom 7% for sg&a expense. SG&A Expense has increased for 9 consecutive years, from $20M in FY2016 to $2.1B in FY2025.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of +28.2%. Top quartile in the Health Care sector.
Increased from $1.5B to $2.1B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- +28.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 213This company $2.1B Sector average $722.3M
▼
+188.2% above sector average
Key checks
Key Insights
- BeOne Medicines Ltd.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +28.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 13.7% year-over-year.
- Ranks #14 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | +13.7% |
| FY2024 | $1.8B | +21.4% |
| FY2023 | $1.5B | +17.9% |
| FY2022 | $1.3B | +29.1% |
| FY2021 | $990.1M | +65.0% |
| FY2020 | $600.2M | +54.6% |
| FY2019 | $388.2M | +98.7% |
| FY2018 | $195.4M | +212.1% |
| FY2017 | $62.6M | +211.5% |
| FY2016 | $20.1M | +174.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026